glp-1 drugs adverse effects nausea: How to handle GLP-1s' most common side effect GLP-1RA Essentials in Gastroenterology: Side

doi: 10.1001/jama.2024.2252 21 ZakariaHAlshehhiSCaccelliMOzkanCKattanJJafaarZet al

Effectiveness and safety of the combination of sodium-glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies

Additional information Competing interests The authors declare that they have no competing interests that would influence the content of this review

Semin Nephrol 27:130143

Once-daily oral semaglutide (Rybelsus) achieves an HbA 1c reduction of around 1115 mmol/mol in people with type 2 diabetes less than injectable semaglutide but comparable to other long-acting injectable GLP-1 RAs

According to the Centers for Disease Control and Prevention, more than 38 million Americans are living with diabetes, supporting sustained demand for GLP-1 receptor agonists across the region